Bladder Cancer

  • Ping Jiang
  • Juergen Dunst
Part of the Medical Radiology book series (MEDRAD)


Bladder cancer is the 9th most common cancer diagnosis worldwide. There are more than 330,000 new cases each year and more than 130,000 deaths per year. Although radical cystectomy has been considered as standard for localised muscle-invasive bladder cancer, there is rapidly growing evidence from numerous phase-II-studies that concurrent radiochemotherapy yields survival rates identical to surgical series but with the chance of bladder preservation in 70% to 80% of long-term survivors. Patients treated in organ-sparing protocols should initially undergo a complete transurethral resection of the bladder tumour (TUR-BT), followed by chemoradiotherapy. Major prognostic factor of the overall remission are the completeness of the TUR-BT prior to radiotherapy and the use of chemotherapy. The overall survival of patients lies in the range of about 50% after 5 years which is nearly identical to cystectomy series. Major prognostic factors for overall survival such as age or T-category etc. are reported. The acute toxicity of radiotherapy is moderate. Late toxicity of organ-preserving treatment protocols is low and compares favourably to series with radical cystectomy. A small number of prognostic factors are well established for patients undergoing radiotherapy or radiochemotherapy for bladder cancer (especially age, T-category and completeness of TUR). Currently, there are few nomograms and prognostic models available; all of them include different clinical prognostic factors. New molecular factors have so far not been sufficiently investigated. Nomograms for toxicity (which is low) are not available.


Bladder Cancer Radical Cystectomy Late Toxicity Major Prognostic Factor Bladder Preservation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Ali-El-Dein B, Sooriakumaran P, Trinh QD, Barakat TS, Nabeeh A, Ibrahiem EH (2013) Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre. BJU Int. doi: 10.1111/bju.12026 PubMedGoogle Scholar
  2. Bochner BH, Kattan MW, Vora KC (2006) Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 24:3967–3972PubMedCrossRefGoogle Scholar
  3. Choudhury A, Nelson LD, Teo MT (2010) MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res 70:7017–7026PubMedCentralPubMedCrossRefGoogle Scholar
  4. Coen JJ, Paly JJ, Niemierko A, Kaufman DS, Heney NM, Spiegel DY, Efstathiou JA, Zietman A, Shipley WU (2013) Normograms predicting response and outcome after bladder-preserving trimodality therapy in muscle-.invasive bladder cancer. Int J Radiat Oncol Biol Phys 86:311–316PubMedCrossRefGoogle Scholar
  5. Dunst J, Rödel C, Zietman A, Schrott KM, Sauer R, Shipley WU (2001) Bladder preservation in muscle-invasive bladder cancer by conservative surgery and radiochemotherapy. Semin Surg Oncol 20:24–32PubMedCrossRefGoogle Scholar
  6. Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, Sandler HM (2009) Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol. 27(25):4055-4061Google Scholar
  7. Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, Coen JJ, Skowronski RY, Paly JJ, McGovern FJ, Zietman AL (2012) Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 61:705–711PubMedCrossRefGoogle Scholar
  8. Fairey AS, Kassouf W, Aprikian AG, Chin JL, Izawa JI, Fradet Y, Lacombe L, Rendon RA, Bell D, Cagiannos I, Drachenberg DE, Lattouf JB, Estey EP (2012) Age ≥ 80 years is independently associated with survival outcomes after radical cystectomy: results from the canadian bladder cancer network Database. Urol Oncol 30:825–832PubMedCrossRefGoogle Scholar
  9. Fossa SD, Aass N, Ous S, Waehre H, Ilner K, Hannisdal E (1996). Survival after curative treatment of muscle-invasive bladder cancer. Acta Oncol 35 Suppl 8:59-65Google Scholar
  10. Gakis G, Todenhöfer T, Renninger M, Schilling D, Sievert KD, Schwentner C, Stenzl A (2011) Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int 108:1800–1805PubMedCrossRefGoogle Scholar
  11. Hannisdal E, Fosså SD, Høst H (1993) Blood tests and prognosis in bladder carcinomas treated with definitive radiotherapy. Radiother Oncol 27:117–122PubMedCrossRefGoogle Scholar
  12. Ishioka J, Saito K, Sakura M, Yokoyama M, Matsuoka Y, Numao N, Koga F, Masuda H, Fujii Y, Kawakami S, Kihara K (2012) Development of a nomogram incorporating serum C-reactive protein level to predict overall survival of patients with advanced urothelial carcinoma and its evaluation by decision curve analysis. Br J Cancer 107:1031–1036PubMedCentralPubMedCrossRefGoogle Scholar
  13. James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Sizer B, Sreenivasan T, Hendron C, Lewis R, Waters R, Huddart RA (2012) Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 366:1477–1488PubMedCrossRefGoogle Scholar
  14. Jenkins BJ, Caulfield MJ, Fowler CG, Badenoch DF, Tiptaft RC, Paris AM, Hope-Stone HF, Oliver RT, Blandy JP (1988) Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive (T2/T3) bladder cancer. Br J Urol 62:343–346PubMedCrossRefGoogle Scholar
  15. Kattan MW (2003) Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Curr Opin Urol 13:111–116PubMedCrossRefGoogle Scholar
  16. Laurberg JR, Brems-Eskildsen AS, Nordentoft I, Fristrup N, Schepeler T, Ulhøi BP, Agerbaek M, Hartmann A, Bertz S, Wittlinger M, Fietkau R, Rödel C, Borre M, Jensen JB, Orntoft T, Dyrskjøt L (2012) Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer. BJU Int 110:E1228–E1236PubMedCrossRefGoogle Scholar
  17. Leissner J, Ghoneim MA, Abol-Enein H et al (2004) Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol 171:139–144PubMedCrossRefGoogle Scholar
  18. Mameghan H, Fisher R, Mameghan J, Brook S (1995) Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 31:247–254PubMedCrossRefGoogle Scholar
  19. May M, Burger M, Brookman-May S, Otto W, Peter J, Rud O, Fritsche HM, Bolenz C, Trojan L, Herrmann E, Michel MS, Wülfing C, Moritz R, Tiemann A, Müller SC, Ellinger J, Buchner A, Stief CG, Tilki D, Wieland WF, Gilfrich C, Höfner T, Hohenfellner M, Haferkamp A, Roigas J, Bretschneider-Ehrenberg P, Müller O, Zacharias M, Gunia S, Bastian PJ (2011) Validation of pre-cystectomy nomograms for the prediction of locally advanced urothelial bladder cancer in a multicentre study: are we able to adequately predict locally advanced tumor stages before surgery? Urologe A 50:706–713PubMedCrossRefGoogle Scholar
  20. Mitra AP, Castelao JE, Hawes D, Tsao-Wei DD, Jiang X, Shi SR, Datar RH, Skinner EC, Stein JP, Groshen S, Yu MC, Ross RK, Skinner DG, Cortessis VK, Cote RJ (2013) Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program. Cancer 119:756–765PubMedCentralPubMedCrossRefGoogle Scholar
  21. Mueller AC, Diestelhorst A, Kuhnt T, Kühn R, Fornara P, Scholz HJ, Dunst J, Zietman AL (1997) Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer. Strahlenther Onkol 183:177–183CrossRefGoogle Scholar
  22. Ploeg M, Aben KK, Kiemeney LA (2009) The present and future burden of urinary bladder cancer in the world. World J Urol 27:289–293PubMedCentralPubMedCrossRefGoogle Scholar
  23. Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ, Bochner BH, Michor F (2012) Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res 18:1323–1333PubMedCentralPubMedCrossRefGoogle Scholar
  24. Roedel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, Meyer M, Schrott KM, Sauer R (2002) Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20:3061–3071CrossRefGoogle Scholar
  25. Roedel C, Grabenbauer GG, Roedel F, Birkenhake S, Kuehn R, Martus P, Zoercher T, Fuersich D, Papadopoulos T, Dunst J, Schrott KM, Sauer R (2000) Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys 46:1213–1221CrossRefGoogle Scholar
  26. Schepeler T, Lamy P, Laurberg JR, Fristrup N, Reinert T, Bartkova J, Tropia L, Bartek J, Halazonetis TD, Pan CC, Borre M, Dyrskjøt L, Orntoft TF (2012). A high resolution genomic portrait of bladder cancer: correlation between genomic aberrations and the DNA damage response. Oncogene. doi: 10.1038/onc.2012.381
  27. Shariat SF, Margulis V, Lotan Y, Montorsi F, Karakiewicz PI (2008) Nomograms for bladder cancer. Eur Urol 54:41–53PubMedCrossRefGoogle Scholar
  28. Shipley WU, Zietman AL, Kaufman DS, Althausen AF, Heney NM (1997) Invasive bladder cancer: treatment strategies using transurethral surgery, chemotherapy and radiation therapy with selection for bladder conservation. Int J Radiat Oncol Biol Phys 39:937–943PubMedCrossRefGoogle Scholar
  29. Skinner DG (1982) Management of invasive bladder cancer: a meticulous pelvic node dissection can make a difference. J Urol 128:34PubMedGoogle Scholar
  30. Todenhoefer T, Renninger M, Schwentner C, Stenzl A, Gakis G (2012) A new prognostic model for cancer-specific survival after radical cystectomy including pretreatment thrombocytosis and standard pathological risk factors. BJU Int 110:E533–E540CrossRefGoogle Scholar
  31. Weiss C, Wolze C, Engehausen DG, Ott OJ, Krause FS, Schrott KM, Dunst J, Sauer R, Roedel C (2006) Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J Clin Oncol 24(15):2318–2324PubMedCrossRefGoogle Scholar
  32. Xylinas E, Cha EK, Sun M, Rink M, Trinh QD, Novara G, Green DA, Pycha A, Fradet Y, Daneshmand S, Svatek RS, Fritsche HM, Kassouf W, Scherr DS, Faison T, Crivelli JJ, Tagawa ST, Zerbib M, Karakiewicz PI, Shariat SF (2012) Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. Br J Cancer 107:1826–1832PubMedCentralPubMedCrossRefGoogle Scholar
  33. Yafi FA, Aprikian AG, Chin JL, Fradet Y, Izawa J, Estey E, Fairey A, Rendon R, Cagiannos I, Lacombe L, Lattouf JB, Bell D, Drachenberg D, Kassouf W (2011) Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int 108:539–545PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Department of Radiation OncologyUniversity Clinic Schleswig-HolsteinKielGermany

Personalised recommendations